Petros Cost Of Revenue vs Tax Provision Analysis

PTPI Stock

USD 0.29 0.02 7.41%

Petros Pharmaceuticals financial indicator trend analysis is much more than just breaking down Petros Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Petros Pharmaceuticals is a good investment. Please check the relationship between Petros Pharmaceuticals Cost Of Revenue and its Tax Provision accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.

Cost Of Revenue vs Tax Provision

Cost Of Revenue vs Tax Provision Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Petros Pharmaceuticals Cost Of Revenue account and Tax Provision. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Petros Pharmaceuticals' Cost Of Revenue and Tax Provision is -0.18. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Tax Provision in the same time period over historical financial statements of Petros Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Petros Pharmaceuticals' Cost Of Revenue and Tax Provision is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Petros Pharmaceuticals are associated (or correlated) with its Tax Provision. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Tax Provision has no effect on the direction of Cost Of Revenue i.e., Petros Pharmaceuticals' Cost Of Revenue and Tax Provision go up and down completely randomly.

Correlation Coefficient

-0.18

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Petros Pharmaceuticals income statement and represents the costs associated with goods and services Petros Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most indicators from Petros Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Petros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.The Petros Pharmaceuticals' current Selling General Administrative is estimated to increase to about 11.6 M, while Tax Provision is projected to decrease to 0.00.

	2021	2022	2023	2024 (projected)
Gross Profit	6.2M	3.7M	4.2M	4.4M
Total Revenue	7.8M	6.0M	5.8M	7.2M

Gross Profit Total Revenue

Petros Pharmaceuticals fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Inventory	Other Current Assets	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total
Other Current Liab		0.32	0.61	0.16	0.0	0.6	0.22	0.38	-0.18	0.47	0.8	-0.48	0.65	-0.52	0.53	0.56	0.01	-0.56	0.55	0.25	0.84	0.48	0.55	-0.29	-0.05	-0.42
Total Current Liabilities	0.32		0.47	-0.84	0.82	0.14	-0.68	0.81	0.56	-0.34	-0.2	0.19	0.9	0.5	-0.41	-0.45	0.89	0.47	-0.49	0.97	0.6	0.05	-0.49	0.74	-0.91	0.06
Other Liab	0.61	0.47		-0.16	0.11	0.57	0.1	0.85	-0.09	0.16	0.26	-0.08	0.55	0.0	-0.06	0.35	0.44	-0.09	0.12	0.37	0.6	0.38	0.12	-0.07	-0.17	0.33
Net Tangible Assets	0.16	-0.84	-0.16		-0.95	0.35	0.92	-0.61	-0.85	0.7	0.67	-0.21	-0.55	-0.87	0.79	0.83	-0.96	-0.86	0.88	-0.88	-0.11	0.29	0.88	-0.97	0.94	-0.36
Retained Earnings	0.0	0.82	0.11	-0.95		-0.43	-0.95	0.51	0.93	-0.7	-0.54	-0.07	0.58	0.78	-0.68	-0.79	0.89	0.79	-0.81	0.88	0.17	-0.24	-0.81	0.94	-0.94	0.21
Accounts Payable	0.6	0.14	0.57	0.35	-0.43		0.57	0.38	-0.72	0.63	0.69	0.31	0.46	-0.64	0.63	0.74	-0.17	-0.69	0.69	0.04	0.75	0.55	0.69	-0.51	0.18	-0.38
Other Assets	0.22	-0.68	0.1	0.92	-0.95	0.57		-0.35	-0.94	0.78	0.67	-0.01	-0.4	-0.83	0.72	0.87	-0.81	-0.87	0.88	-0.79	0.03	0.45	0.88	-0.96	0.91	-0.24
Net Receivables	0.38	0.81	0.85	-0.61	0.51	0.38	-0.35		0.27	-0.15	-0.09	0.19	0.74	0.38	-0.39	-0.1	0.8	0.31	-0.29	0.75	0.58	0.1	-0.29	0.42	-0.63	0.39
Inventory	-0.18	0.56	-0.09	-0.85	0.93	-0.72	-0.94	0.27		-0.76	-0.65	-0.24	0.27	0.84	-0.76	-0.86	0.75	0.86	-0.87	0.66	-0.15	-0.42	-0.87	0.9	-0.78	0.34
Other Current Assets	0.47	-0.34	0.16	0.7	-0.7	0.63	0.78	-0.15	-0.76		0.84	-0.02	-0.03	-0.82	0.69	0.7	-0.6	-0.85	0.86	-0.47	0.27	0.15	0.86	-0.74	0.58	-0.34
Total Current Assets	0.8	-0.2	0.26	0.67	-0.54	0.69	0.67	-0.09	-0.65	0.84		-0.33	0.22	-0.92	0.88	0.83	-0.55	-0.93	0.92	-0.28	0.59	0.41	0.92	-0.73	0.45	-0.61
Common Stock	-0.48	0.19	-0.08	-0.21	-0.07	0.31	-0.01	0.19	-0.24	-0.02	-0.33		0.08	0.17	-0.15	-0.17	0.16	0.17	-0.17	0.15	-0.01	-0.07	-0.17	0.19	-0.17	0.06
Total Assets	0.65	0.9	0.55	-0.55	0.58	0.46	-0.4	0.74	0.27	-0.03	0.22	0.08		0.08	0.02	-0.07	0.63	0.06	-0.08	0.86	0.88	0.25	-0.08	0.42	-0.73	-0.27
Short Long Term Debt Total	-0.52	0.5	0.0	-0.87	0.78	-0.64	-0.83	0.38	0.84	-0.82	-0.92	0.17	0.08		-0.97	-0.89	0.81	0.99	-0.99	0.55	-0.35	-0.42	-0.99	0.88	-0.68	0.67
Total Stockholder Equity	0.53	-0.41	-0.06	0.79	-0.68	0.63	0.72	-0.39	-0.76	0.69	0.88	-0.15	0.02	-0.97		0.83	-0.76	-0.95	0.93	-0.43	0.44	0.5	0.93	-0.79	0.57	-0.81
Property Plant And Equipment Net	0.56	-0.45	0.35	0.83	-0.79	0.74	0.87	-0.1	-0.86	0.7	0.83	-0.17	-0.07	-0.89	0.83		-0.66	-0.91	0.93	-0.51	0.39	0.56	0.93	-0.92	0.7	-0.37
Current Deferred Revenue	0.01	0.89	0.44	-0.96	0.89	-0.17	-0.81	0.8	0.75	-0.6	-0.55	0.16	0.63	0.81	-0.76	-0.66		0.78	-0.78	0.9	0.24	-0.17	-0.78	0.87	-0.9	0.46
Net Debt	-0.56	0.47	-0.09	-0.86	0.79	-0.69	-0.87	0.31	0.86	-0.85	-0.93	0.17	0.06	0.99	-0.95	-0.91	0.78		-1.0	0.55	-0.38	-0.49	-1.0	0.9	-0.7	0.61
Cash	0.55	-0.49	0.12	0.88	-0.81	0.69	0.88	-0.29	-0.87	0.86	0.92	-0.17	-0.08	-0.99	0.93	0.93	-0.78	-1.0		-0.56	0.36	0.46	1.0	-0.92	0.71	-0.56
Non Current Assets Total	0.25	0.97	0.37	-0.88	0.88	0.04	-0.79	0.75	0.66	-0.47	-0.28	0.15	0.86	0.55	-0.43	-0.51	0.9	0.55	-0.56		0.55	-0.06	-0.56	0.8	-0.97	0.05
Non Currrent Assets Other	0.84	0.6	0.6	-0.11	0.17	0.75	0.03	0.58	-0.15	0.27	0.59	-0.01	0.88	-0.35	0.44	0.39	0.24	-0.38	0.36	0.55		0.52	0.36	-0.04	-0.34	-0.49
Long Term Debt	0.48	0.05	0.38	0.29	-0.24	0.55	0.45	0.1	-0.42	0.15	0.41	-0.07	0.25	-0.42	0.5	0.56	-0.17	-0.49	0.46	-0.06	0.52		0.46	-0.39	0.26	-0.42
Cash And Short Term Investments	0.55	-0.49	0.12	0.88	-0.81	0.69	0.88	-0.29	-0.87	0.86	0.92	-0.17	-0.08	-0.99	0.93	0.93	-0.78	-1.0	1.0	-0.56	0.36	0.46		-0.92	0.71	-0.56
Common Stock Total Equity	-0.29	0.74	-0.07	-0.97	0.94	-0.51	-0.96	0.42	0.9	-0.74	-0.73	0.19	0.42	0.88	-0.79	-0.92	0.87	0.9	-0.92	0.8	-0.04	-0.39	-0.92		-0.91	0.3
Common Stock Shares Outstanding	-0.05	-0.91	-0.17	0.94	-0.94	0.18	0.91	-0.63	-0.78	0.58	0.45	-0.17	-0.73	-0.68	0.57	0.7	-0.9	-0.7	0.71	-0.97	-0.34	0.26	0.71	-0.91		-0.11
Non Current Liabilities Total	-0.42	0.06	0.33	-0.36	0.21	-0.38	-0.24	0.39	0.34	-0.34	-0.61	0.06	-0.27	0.67	-0.81	-0.37	0.46	0.61	-0.56	0.05	-0.49	-0.42	-0.56	0.3	-0.11

Click cells to compare fundamentals

Petros Pharmaceuticals Account Relationship Matchups

Petros Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	453.1K	29.1M	26.4M	4.0M	7.8M	10.7M
Total Current Liabilities	41.1M	41.9M	31.0M	7.1M	10.8M	10.2M
Retained Earnings	(41.1M)	(61.7M)	(70.7M)	(90.7M)	(98.9M)	(93.9M)
Accounts Payable	3.8M	5.6M	4.6M	1.8M	1.7M	2.6M
Net Receivables	3.8M	5.2M	2.5M	2.1M	2.2M	2.6M
Inventory	2.2M	760.5K	519.6K	1.8M	1.6M	1.8M
Other Current Assets	1.9M	2.9M	3.1M	1.3M	3.2M	2.6M
Total Current Assets	12.1M	25.9M	30.5M	14.7M	20.4M	21.9M
Common Stock	29.1M	971.0	2.1K	208.0	298.0	283.1

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:

How To Invest In Petros

Details

Is Petros Stock a good investment?

Details

What is Petros Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.80)

Revenue Per Share

0.99

Quarterly Revenue Growth

(0.29)

Return On Assets

(0.31)

Return On Equity

(0.64)

The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Petros Cost Of Revenue vs Tax Provision Analysis

Cost Of Revenue vs Tax Provision

Cost Of Revenue vs Tax Provision Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Tax Provision

Petros Pharmaceuticals fundamental ratios Correlations

Petros Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Petros Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Net Debt	+ 0.99	Short Long Term Debt Total
Non Current Assets Total	+ 0.97	Total Current Liabilities
Common Stock Shares Outstanding	+ 0.94	Net Tangible Assets
Common Stock Total Equity	+ 0.94	Retained Earnings
Inventory	+ 0.93	Retained Earnings

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.99	Short Long Term Debt Total
Cash	- 0.99	Short Long Term Debt Total
Common Stock Shares Outstanding	- 0.97	Non Current Assets Total
Total Stockholder Equity	- 0.97	Short Long Term Debt Total